# Abbott Completes $21 Billion Acquisition of Exact Sciences

> ma · REPORTED · 2026-03-27

Abbott completed its acquisition of Exact Sciences, making it a wholly owned subsidiary and adding approximately $3 billion in incremental annual sales. The deal, one of the largest medtech transactions of 2026, unites Abbott's global diagnostics infrastructure with Exact Sciences' Cologuard colorectal cancer screening test, Oncotype DX precision oncology assay, and multi-cancer early detection pipeline.

About Abbott / Exact Sciences: Exact Sciences is a cancer diagnostics company that develops and commercializes noninvasive screening and precision oncology tests, including Cologuard for colorectal cancer and Oncotype DX for breast cancer treatment guidance, serving patients and oncologists across the US.

- Company: Abbott / Exact Sciences
- Sector: diagnostics
- Primary source: https://www.massdevice.com/abbott-completes-exact-sciences-acquisition/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.